Stakeholder Opinions: Hematopoietic Stem Cell Transplantation - In need of further research and development
Published By: Datamonitor
April 2009
R313-50617
Online Download $3,800.00
Global Site License $9,500.00
Description
Introduction
Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes.
Scope- Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens
- Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends
- Unmet needs and research priorities in the field of HSCT
- Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights
The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.
The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.
The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.
Reasons to Purchase- Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens
- Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
- Identify unmet needs and research priorities in the field of HSCT
Please note: this is delivered as a Zip file.
|
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of analysis
- Datamonitor insight into hematopoietic stem cell transplantation
- Contributing experts
- Related reports
- Upcoming reports
- CHAPTER 2 HEMATOPOIETIC STEM CELL TRANSPLANTATION OVERVIEW
- Definition
- Overview of the hematopoietic stem cell transplantation procedure
- Use and applications of hematopoietic stem cell transplantation
- Types of stem cell transplants
- Stem cell donors
- Allogeneic transplants
- Autologous transplants
- Stem cell sources
- Bone marrow
- Peripheral blood
- Umbilical cord blood
- Conditioning
- Myeloablative conditioning
- Reduced-intensity conditioning (RIC) and nonmyeloablative conditioning
- Mortality and survival data
- CHAPTER 3 PHARMACOLOGIC USE
- Conditioning regimens
- Myeloablative regimens
- Reduced-intensity conditioning
- Conditioning by type of hematologic malignancy
- Research & development in the conditioning field
- Molecular targeted therapies
- Radioimmunotherapy
- Prophylaxis and treatment of hematopoietic stem cell transplantation complications
- Early complications
- Acute graft-versus-host disease (GVHD)
- Late complications
- Chronic graft-versus-host disease (GVHD)
- Secondary malignancies
- Other areas of research & development
- Augmentation of the graft-versus-tumor (GVT) effect
- Expansion of allogeneic HSCT to solid tumors
- CHAPTER 4 UNMET NEEDS & RESEARCH PRIORITIES
- Key findings
- Unmet needs and research priorities in hematopoietic stem cell transplantation
- HSCT remains an underutilized treatment
- Relapse remains the main cause of death after HSCT
- HSCT is in need of an overall refinement
- The effective management of graft-versus-host disease is considered a priority
- BIBLIOGRAPHY
- APPENDIX
- List of tables
- List of figures
- About Datamonitor
- About Datamonitor Healthcare
- About the Oncology analysis team
- Disclaimer
- List of Tables
- Table 1: Hematopoietic stem cell transplantation: definitions
- Table 2: Donor types for allogeneic hematopoietic stem cell transplantation
- Table 3: Comparison of stem cell sources for hematopoietic stem cell transplantation
- Table 4: Reduced-intensity conditioning (RIC) and nonmyeloablative regimens: mode of action
- Table 5: Three-year survival rates for patients with acute myeloid leukemia and diffuse large B-cell lymphoma
- Table 6: Examples of radiation-based conditioning regimens used in hematopoietic stem cell transplantation
- Table 7: Examples of chemotherapy-based conditioning regimens used in hematopoietic stem cell transplantation
- Table 8: Examples of reduced-intensity conditioning regimens used in hematopoietic stem cell transplantation
- Table 9: Examples of conditioning regimens used in hematopoietic stem cell transplantation by type of hematologic malignancy
- Table 10: Investigation of Rituxan and Campath in regimens used in hematopoietic stem cell transplantation conditioning
- Table 11: Investigation of anti-CD20 radioimmunotherapy in hematopoietic stem cell transplantation conditioning
- Table 12: Early complications of hematopoietic stem cell transplantation
- Table 13: Selected drugs available for use in the prophylaxis of acute graft-versus-host disease
- Table 14: Selected drugs investigated in the treatment of steroid-refractory acute graft-versus-host disease
- Table 15: Drugs/therapies in company-sponsored Phase III development for graft-versus-host disease as their primary indication, 2009
- Table 16: Late complications of hematopoietic stem cell transplantation
- Table 17: Selected drugs investigated in the treatment of steroid-refractory chronic graft-versus-host disease
- List of Figures
- Figure 1: The normal hematopoiesis process
- Figure 2: Overview of the hematopoietic stem cell transplantation procedure
- Figure 3: The applications of autologous and allogeneic hematopoietic stem cell transplantation
- Figure 4: Main indications for hematopoietic stem cell transplantation in 2007, according to EBMT data
- Figure 5: Indications for allogeneic hematopoietic stem cell transplantation worldwide in 2005, according to CIBMTR data
- Figure 6: Annual number of hematopoietic stem cell transplantations worldwide, 1970-2006, according to CIBMTR data
- Figure 7: Stem cell sources for allogeneic and autologous transplants in patients over 20 years of age, 1997-2006, according to CIBMTR data
- Figure 8: The use of myeloablative and reduced-intensity conditioning regimens in allogeneic transplants, 1998-2006 according to CIBMTR data
- Figure 9: Age distribution of patients receiving allogeneic transplants by conditioning regimen intensity, 2005-06, according to CIBMTR data
- Figure 10: Causes of death after transplantations, 2001-06, according to CIBMTR data
- Figure 11: Unmet needs and research priorities in hematopoietic stem cell transplantation
|
Order Form * Please reference product number R313-50617 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
